Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression

Retrovirology

Table 1 Patient clinical status, CD4 count at time of virus isolation, time to/from AIDS diagnosis and coreceptor use of primary isolates studied.

Patient^a	Isolate	CD4 count^b	Months to AIDS^c	Clinical status^d	Coreceptor use^e
G	1228	260	-9	Chronic AS	R5
	4481	5	+26	End-stage AIDS	R5
H	624	290	-27	Chronic AS	R5
	3899	6	+6	End-stage AIDS	R5
I	5013	140	-30	Chronic AS	R5
	8616	90	+11	End-stage AIDS	R5
J	1372	220	-11	Chronic AS	R5
	5714	20	+20	End-stage AIDS	R5
L	462	220	-44	Chronic AS	R5
	3932	13	+/-0	End-stage AIDS	R5
M	668	750	-54	Chronic AS	R5
	7363	20	+20	End-stage AIDS	R5
R	6322	200	-2	Chronic AS	R3R5
	8004	9	+16	End-stage AIDS	R3R5

a) Patient code according to [7].
b) CD4⁺ T cells/μl at time of virus isolation.
c) Time point of virus isolation related to months before and after AIDS diagnosis.
d) Patient status at time of virus isolation. AS = asymptomatic or with mild symptoms not classified as AIDS, AIDS = acquired immunodeficiency syndrome.
e) Coreceptor use determined by infection of U87.CD4 and GHOST coreceptor indicator cell lines expressing CCR2b, CCR3, CCR5, CXCR4, CXCR6 or BOB [7].

ISSN: 1742-4690